EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade) [Seeking Alpha]
EyePoint Pharmaceuticals, Inc. (EYPT)
Last eyepoint pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Summary EyePoint Pharmaceuticals' Duravyu shows promise as a long-acting therapy for Wet AMD, potentially rivaling Regeneron's Eylea with its six-month dosing frequency. Positive Phase 2 Davio study data boosted EyePoint's stock, but concerns remain about efficacy, financial strength, competition, and patient/physician adoption. A recent NPDR study failure caused a significant stock drop, but upcoming Phase 3 Wet AMD and Phase 2 DME data could provide new catalysts for gains. Despite risks, I upgrade EyePoint to "Buy" due to potential price volatility and multiple upcoming data catalysts that could drive significant gains. bluecinema/E+ via Getty Images Investment Overview: Promise Of Durasert - Long-Acting Therapy Emerges As Potential Eylea Rival At the end of May 2023 , I gave EyePoint Pharmaceuticals, Inc. ( NASDAQ: EYPT ) stock a "Buy" rating, suggesting that the company and its long-acting Durasert Recommended For You About EYPT Stock
Show less
Read more
Impact Snapshot
Event Time:
EYPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EYPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EYPT alerts
High impacting EyePoint Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
EYPT
News
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
- EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of DirectorsGlobeNewswire
- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $15.00 price target on the stock.MarketBeat
- EyePoint Pharmaceuticals Announces Participation at Upcoming Investor ConferencesGlobeNewswire
EYPT
Earnings
- 8/7/24 - Miss
EYPT
Sec Filings
- 9/5/24 - Form 4
- 9/5/24 - Form 3
- 9/4/24 - Form 8-K
- EYPT's page on the SEC website